James E. Flynn and his fund, Deerfield Management, have disclosed a stake in Audentes Therapeutics Inc (NASDAQ:BOLD), a company that has recently closed its initial public offering. According to a filing with the Securities and Exchange Commission, Flynn and Deerfield hold roughly 1.4 million shares, which account for some 6.68% of the company’s outstanding stock.
Audentes Therapeutics Inc (NASDAQ:BOLD) is a biotechnology company that aims to develop gene therapy for various rare diseases. The company sold 5 million shares at $15 apiece in its initial offering, raising $75 million that it plans to invest in its research work. Among the main conditions it is now studying are X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease. The drug candidates for these three conditions are expected to produce preliminary results from their first trials during the second half of 2017.
Samuel Isaly‘s OrbiMed Advisors had also invested in Audentes Therapeutics Inc (NASDAQ:BOLD) before the initial public offering and was the largest shareholder with a 29.8% stake prior to the offering. Overall, since its inception in 2012, Audentes Therapeutics has raised $135.8 million in equity financing from various venture capitalists and private investors, as well as hedge funds.
RAJ CREATIONZS / shutterstock.com
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 514,424 | 0 | 514,424 | 514,424 | 2.45% |
| Deerfield Management Company | 0 | 1,403,654 | 0 | 1,403,654 | 1,403,654 | 6.68% |
| Deerfield Mgmt III | 0 | 889,230 | 0 | 889,230 | 889,230 | 4.23% |
| Deerfield Special Situations Fund | 0 | 514,424 | 0 | 514,424 | 514,424 | 2.45% |
| Deerfield Private Design Fund III | 0 | 889,230 | 0 | 889,230 | 889,230 | 4.23% |
| James E. Flynn | 0 | 1,403,654 | 0 | 1,403,654 | 1,403,654 | 6.68% |
Page 1 of 14 – SEC Filing
Audentes Therapeutics, Inc.
Common Stock, par value $0.00001 per share
05070R104
July 25, 2016
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Why These Five Stocks Are Trending Today
Short Interest is Tapering Off in These 5 Nasdaq Stocks
A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate
Two Under The Radar Biotech Decisions To Watch Next Month
5 Prominent NYSE Stocks That Hit 52-Week Highs Monday
Here’s Why These Five Stocks Are on the Move
